Devices to diagnose Alzheimer’s, latent tuberculosis receive awards in DEBUT contest – Patient Daily

The University of Maryland's EEG model that undergraduates created to aid in identifying Alzheimer's disease. The model won the National Institute of Biomedical Imaging and Bioengineering's top monetary reward in the 2017 DEBUT contest. | University of Maryland College Park

Tools created by college undergraduates that help identify Alzheimer's disease and latent tuberculosis were recognized in the Design by Biomedical Undergraduate Teams (DEBUT) contest.

The National Institute of Biomedical Imaging and Bioengineering and VentureWell chose three winning teams from groups representing 22 universities from 16 states that turned in 41 contenders. The teams were chosen by determining the significance of the disorder,how designs would affect doctors' work and whether they could show a working prototype.

The National Institute of Biomedical Imaging and Bioengineering awarded the $20,000 top prize to University of Maryland undergraduates who created a device that aids in diagnosing Alzheimer's disease.

VentureWell chose two more groups by determining the commercial viability of the teams' devices and thechances of getting a patent. VentureWell gave a Venture Prize worth $15,000 to George Mason University undergraduates who created a device that aids in diagnosing tuberculosis that hasn't been found yet.

Additionally, the $5,000 Design Excellence award was given to a Johns Hopkins University team that created a discreet nasal dilator that helps with breathing.

The groups will receive their prizes in a celebration Oct. 12 at the Biomedical Engineering Society conference in Phoenix.

The National Institutes of Health, the National Institute of Biomedical Imaging and Bioengineering and VentureWell sponsor the DEBUT contest, which gives out winnings valued at $65,000. The National Institute of Biomedical Imaging and Bioengineering partnered with VentureWell for the second year.

Go here to read the rest:
Devices to diagnose Alzheimer's, latent tuberculosis receive awards in DEBUT contest - Patient Daily

Discovery of a New Compound Turns on a Longevity Gene in Mice – Anti Aging News

New compound provides an observed 90% increase in the activation of the gene's activation in the animal's heart tissue

The University of Hawaii Cancer Center has developed a compound called Astaxanthin that turns on whats called the FOX03 'Longevity Gene' in mice. Their scientists measured an almost a 90% increase in the activation of the gene in the animals' heart tissue.

In a joint venture, The University of Hawaii John A. Burns School of Medicine ("JABSOM") and Cardax, Inc. ("Cardax") (OTCQB:CDXI), a Honolulu based life sciences company revealed their promising results toward a new anti-aging therapy

Dr. Bradley Willcox, MD, Professor and Director of Research at the Department of Geriatric Medicine, JABSOM, and Principal Investigator of the National Institutes of Health-funded Kuakini Hawaii Lifespan and Healthspan Studies states, "All of us have the FOXO3 gene, which protects against aging in humans," said. "But about one in three persons carry a version of the FOXO3 gene that is associated with longevity. By activating the FOXO3 gene common in all humans, we can make it act like the "longevity" version. Through this research, we have shown that Astaxanthin "activates" the FOXO3 gene," said Willcox.

"This preliminary study was the first of its kind to test the potential of Astaxanthin to activate the FOXO3 gene in mammals," said Dr. Richard Allsopp, PhD, Associate Professor, and researcher with the JABSOM Institute of Biogenesis Research.

Experiments with the mice the control group was fed regular food and the other group was either a low or high amount of Astaxanthin compound CDX-085 provided by Cardax. As expected the group with higher doses gained the greatest increase in the FOXO3 gene in their heart tissue. "We found a nearly 90% increase in the activation of the FOXO3 "Longevity Gene" in the mice fed the higher dose of the Astaxanthin compound CDX-085," said Dr. Allsopp.

"This groundbreaking University of Hawaii research further supports the critical role of Astaxanthin in health and why the healthcare community is embracing its use," said David G. Watumull, Cardax CEO. "We look forward to further confirmation in human clinical trials of Astaxanthin's role in aging."

"We are extremely proud of our collaborative efforts with Cardax on this very promising research that may help mitigate the effects of aging in humans," said Vassilis L. Syrmos, Vice President of Research at the University of Hawaii. "This is a great example of what the Hawaii Innovation Initiative is all about -- when the private sector and government join forces to build a thriving innovation, research, education and job training enterprise to help diversify the state's economy."

Life sciences company Cardax, Inc. looks forward to further confirmation in human clinical trials of Astanxanthin's potential role as an anti-aging therapy.

Dr. Michael J. Koch, Editor withwww.WorldHealth.net and for Dr. Ronald Klatz, DO, MD President of the A4M has 28,000 Physician Members, has trained over 150,000 Physicians, health professionals and scientists in the new specialty of Anti-aging medicine. Estimates of their patients numbering in the 100s of millions World Wide that are living better stronger, healthier and longer lives. A4M physicians are now providing advanced preventative medical care for over 100 Million individuals worldwide who now recognize that aging is no longer inevitable.

Go here to see the original:
Discovery of a New Compound Turns on a Longevity Gene in Mice - Anti Aging News

Grey’s Anatomy: We Need to Talk About Jaggie – TV Guide

Now PlayingGrey's Anatomy 7 Worst Couples/Hookups, Ranked

Ever since Season 1 of Grey's Anatomy, fans have joked about the "incestuous" relationships among the show's doctors. Despite being close enough to their colleagues to consider them family, the doctors and residents at Grey Sloan (nee Seattle Grace) often found themselves falling into bed together. Like, really often.

But as the show prepares to enter its 14th season, the term "incest" may no longer be such a misnomer -- and some fans aren't having it.

We're talking, of course, about the budding romance between step-siblings Maggie Pierce (Kelly McCreary) and Jackson Avery (Jesse Williams), a pairing that seemed to emerge out of nowhere when none other than Jackson's ex-wife April (Sarah Drew) told Maggie it was clear Jackson had feelings for her in the Season 13 finale.

(via giphy)

Well, OK, maybe the spark didn't come out of nowhere. Maggie did turn to Jackson for support after her mother died in Season 13 -- even though he had kept Mrs. Pierce's condition a secret from Maggie while he was treating her. After that, they certainly seemed to grow closer at the hospital. But April's observation still came a little out of left field.

Grey's Anatomy Mega Buzz: Are Maggie and Jackson Actually a Thing?

After her failed romance with DeLuca (Giacomo Gianniotti) and unrequited crush on Riggs (Martin Henderson), it sounds like Maggie is just eenie-meenie-miney-mo'ing her way around the men at her workplace, without much success. Would it kill her (or any of the other doctors, for that matter) to maybe try an online dating service for once?

And a Maggie-Jackson romance provides yet another very convenient roadblock to keep Jackson and April -- a popular couple shipped by many fans who share a child, have their own hashtag (#Japril) and had an entire episode devoted to themselves last season -- apart for at least the better part of another year.

Also, and I believe I mentioned this earlier: the two are step-siblings. Maggie's father Richard (James Pickens Jr.) is married to Jackson's mother Catherine (Debbie Allen). What is this, Game of Thrones?

Whether Maggie and Jackson will actually take the plunge remains to be seen, but fans seem to be pretty divided about the potential pairing.

This week, Williams himself noted that fans seem to be "evenly divided" over the issue, but seemed to maybe indicate that he's not on board with it, retweeting a fan-made anti-Jaggie meme with the simple observation, "Very good."

Look, don't get me wrong: ever since Maggie's character was introduced at the end of Season 10, she's been one of the more interesting and likable characters on the show -- but has suffered nothing but heartache. The closest we've seen her come to having a relationship was her short-lived dalliances with DeLuca and her mostly offscreen stint with the radiologist Ethan. It would be great to see Maggie in a long-term, fulfilling relationship, the likes of which we've seen almost all of the other Grey's characters involved in. Not only is it about time for Maggie to have something good happen to her, giving her a significant other would also provide a wealth of potential drama for a character who longs for a partner -- despite having made her studies and career a priority for her whole life (and who we know has deemed herself incapable of sleeping next to other people).

But a Maggie-Jackson pairing seems like merely a plot device, an arbitrary pairing-off that makes Maggie little more than a pawn in the larger #Japril storyline. There's no denying that there is chemistry between Williams and McCreary; but up until this point it's seemed to be more of the brother/sister variety because, well, that's what they are. Plus, with so many fans already voicing their disdain for the romance before it's even officially happened, it will be a difficult task for the writers and actors to develop the two characters into a couple worth rooting for. And the alternative -- turning viewers against one or both of the mostly beloved characters -- is almost worse. It would be a better idea to put the idea of Jaggie to bed rather than in one.

Also, ew.

Grey's Anatomy kicks off Season 14 with a two-hour premiere Thursday, Sept. 28 at 8/7c on ABC.

Follow this link:
Grey's Anatomy: We Need to Talk About Jaggie - TV Guide

The Anatomy of an Upset: How South can beat Ole Miss – WKRG

MOBILE, Ala. As far as this Saturday, we know Ole Miss is a very good opponent, said South Alabama coach Joey Jones. Were ready to go to a SEC school, and a SEC stadium to play a ballgame. Its exciting for our players.

The anatomy of an upset. It all starts with a mindset. A belief anything is possible.

Theyre not intimidated by the venue. Weve been to Tennessee, weve been to South Carolina and Mississippi State, said Jones. I think they have a little chip on their shoulder. They want to show people what they can do.

To pull off an upset, you have to be prepared. The Jags have been in fall camp for nearly a month.

They know toughness is going to win. They know toughness is going to win on the road. Toughness is going to win those close ballgames, said Jones.

And they have more depth than ever.

A crucial component if you want to beat a SEC foe.

If you look at it over the years, most of those games we sort of wore down at the end of the game. They would kind of get us late in the fourth quarter because were just tired. So having those fresh legs in their will certainly make a difference, said Jones.

Depth, preparation and a belief in yourself and your unit, the necessary ingredients to pull off an upset.

Now its time to put it all to the test.

Were going to bring this program to the next level. Thats our goal this year, said Jones.

Follow this link:
The Anatomy of an Upset: How South can beat Ole Miss - WKRG

White Lotus Products Available on CompleteBeautyStore.com – Benzinga

White Lotus, a company known for its products that adhere to the principles of ancient Chinese medicine to provide anti-aging solutions, announced its products are now ready to be ordered from CompleteBeautyStore.com.

Boca Raton (PRWEB) August 29, 2017

White Lotus, a company known for its products that adhere to the principles of ancient Chinese medicine to provide anti-aging solutions, announced its products are now ready to be ordered from CompleteBeautyStore.com.

The company focuses on producing and distributing holistic anti-aging products. Founded in 2007, White Lotus is different from mainstream beauty companies in that its products are all based on principles of ancient Eastern medicine. Anthony and Kamila Kingston started the Australia-based company after traveling around the world to learn about Chinese medicine. The company's products are now on specialty beauty sites as well as major retail platforms like Amazon.com and Jet.com.

"We're excited to announce White Lotus products will be available from CompleteBeautyStore.com," said Anthony Kingston. "As we focus on expanding our reach in the US market, we want to make our products available to all consumers. White Lotus offers a unique approach in the crowded beauty and cosmetics sector by offering holistic anti-aging solutions that have stood the test of time."

White Lotus is filling a demand in the market for Chinese medicine and acupuncture products. These are designed to enhance skin health, resolve chronic pain problems, prevent hair loss, and eliminate signs of aging such as scars, marks, and wrinkles. The company has developed a reputation for holding impeccable standards of research and testing of its products. Therefore, it can deliver on its promise to provide users with healthier, smoother skin.

White Lotus has a popular line of anti-aging serums. These products are designed to remove aging signs such as cellulite and stretch marks. The jade product line is also popular and gaining traction in the US market. For instance, the jade roller improves lymphatic drainage, skin smoothness and microcirculation, offering users the kind of luxury and relaxation typically reserved for people who come to one of Australia's White Lotus clinics.

"It's our goal to introduce more customers to tried-and-true Eastern principles of skin care," said Kingston. "This new partnership with CompleteBeautyStore.com will help us reach a broader audience."

For more information about White Lotus and its products, visit http://www.whitelotusantiaging.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14635833.htm

Read more here:
White Lotus Products Available on CompleteBeautyStore.com - Benzinga

Metformin could be the first FDA approved antiaging drug – Next Big Future

For the last two decades, researchers started comparing the health of diabetics on metformin to those taking other diabetes drugs.

Metformin-takers tended to be healthier in all sorts of ways. They lived longer and had fewer cardiovascular events, and in at least some studies they were less likely to suffer from dementia and Alzheimers. Most surprising of all, they seemed to get cancer far less frequentlyas much as 25 to 40 percent less than diabetics taking two other popular medications. When they did get cancer, they tended to outlive diabetics with cancer who were taking other medications.

Lewis Cantley, the director of the Cancer Center at Weill Cornell Medicine, once put it, Metformin may have already saved more people from cancer deaths than any drug in history. Nobel laureate James Watson (of DNA-structure fame), who takes metformin off-label for cancer prevention, once suggested that the drug appeared to be our only real clue into the business of fighting the disease.

Metformin is from an ancient herb and the herb has been prescribed since medieval times. Metformin can cost 5 cents per pill.

Metformin is already prescribed off-label to treat obesity, polycystic ovarian syndrome, infertility, nonalcoholic fatty liver disease, and acne.

Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine in the Bronx, like most in his field, was aware of the good news about metformin that had been trickling out year after year.

Barzilai is confident that metformin is good enough to be the first treatment approved by the FDA to counter aging. He has maintained this confidence ever since he read a 2014 study that reviewed the fate of 90,400 type 2 diabetics taking either metformin or another medication. The metformin patients in the study not only outlived the diabetics taking the other druga not especially surprising result if metformin is a superior treatmentbut also outlived the nondiabetics studied as a comparison.

The FDA will not make its decision on whether metformin becomes the USs first antiaging drug until the study, dubbed Targeting Aging with Metformin (TAME for short), is complete. That wont happen for at least another five years. But, based on their June 2015 meeting with FDA officials, Barzilai and his colleagues are optimistic that the FDA is onboard. Within five minutes, we were all in complete agreement that this is plausible and a good idea, S. Jay Olshansky says.Thus far, getting the FDA excited about TAME has proven to be less challenging than convincing someone to pay for the study. Because metformin is a generic, there is no pot of gold waiting for investors at the end of the process. The TAME trial, which will enroll approximately 3,000 men and women between the ages of 65 and 79 at 14 centers across the country, is projected to cost $69 million. Barzilai is counting on the National Institutes of Health to cover a significant share of the cost, and he has been directly involved in lobbying the agency to back the study. Robert Hariri, cofounder and president of genetic sequencing pioneer Craig Venters Human Longevity Cellular Therapeutics, noted during the discussion that he takes metformin (he claims that it has improved his eyesight), as do Ray Kurzweil, of Singularity fame, and Ned David, cofounder of Silicon Valley startup Unity Biotechnology, which is developing its own antiaging drugs.

Read the original:
Metformin could be the first FDA approved antiaging drug - Next Big Future

Balance and Gait Problems can be Improved using Avatars – Anti Aging News

Use of brain-computer interface, virtual avatar could help people with gait disabilities

World Health and A4M have been following gait problems for years in terms of the way balance effect falling and the progression of aging. The role of the American Academy of Anti-Aging Medicine is to support investigators in their goal of attenuation and/or reversing some of the aging process.

The study, funded by the National Institute of Neurological Disease and Stroke, was published this week inScientific Reports. Senior author and researcher Jose Luis Contreras-Vidal is the professor of electrical and computer engineering at University of Houstons Noninvasive Brain-Machine Interface System Laboratory. He is also the site director of the BRAIN Center (Building Reliable Advances and Innovation in Neurotechnology), a National Science Foundation Industry/University Cooperative Research Center. His teams studies are the first to prove that using an interface between a proprietary computer program and a human brain depicting another person walking (avatar) may help balance patients improve gait and return to normal walking following spinal cord or other injury or cerebral vascular injury (stroke). He says that this is the first to involve humans, even though other studies on other primates have been perform previously.

Contreras-Vidal and researchers performed the study by using three trials with 80 healthy graduate students in the UH Department of Electrical and Computer Engineering to provide baseline data. The subjects walked on a treadmill while watching the avatar on a large screen in order to provide increased visual input while wearing a 64-channel EEG skull cap in addition to sensors on ankle, knee and hip joints. The non-invasive brain monitoring helped determine what parts of the brain are involved in walking. They then created an algorithm for a computer-brain interface.

His team wrote. "Voluntary control of movements is crucial for motor learning and physical rehabilitation," "Our results suggest the possible benefits of using a closed-loop EEG-based BCI-VR (brain-computer interface-virtual reality) system in inducing voluntary control of human gait." Up till this point, no one had researched whether a computer assisted algorithm and avatar might actually be effective in promoting better gait, balance and stability.

The subject was connected to the computer via the skull cap and sensors so that the interface caused the avatar on the screen to mimic the subject. The study reported increased activity in the posterior parietal cortex and the inferior parietal lobe, as well as the anterior cingulate cortex; all of which are involved in motor memory. Eventually the subject was actually able to control the avatar with their own brain although much less accurately. Future studies will likely be more accurate as software and interfaces improve. Contreras-Vidal said, "It's like learning to use a new tool or sport," he said. "You have to understand how the tool works. The brain needs time to learn that." The subject of Contreras-Vidal upcoming Ph.D. dissertation is the use of this protocol with actual patients. "The appeal of brain-machine interface is that it places the user at the center of the therapy," Contreras-Vidal said. "They have to be engaged, because they are in control."

Visit link:
Balance and Gait Problems can be Improved using Avatars - Anti Aging News

Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 – Markets Insider

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, which will be held September 8 12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: http://www.esmo.org.

Abstract #1490: Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer:5-year analysis of the Phase III ExteNET trial.The abstract will be presented as a proffered paper oral session on Friday, September 8.

Abstract #177P:Effects of neratinib on health-related quality of life in early stage HER2-positive breast cancer.The abstract will be displayed as a poster on Monday, September 11.

The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer.

U.S. Approval of Neratinib (NERLYNX)

Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets.

About HER2-Positive Breast Cancer

Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

Indication

NERLYNX is a tyrosine kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance.More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

The full prescribing information for NERLYNX is available at http://www.NERLYNX.com. The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

Important Safety Information

There are possible side effects of NERLYNX. Patients must contact their doctor right away if they experience any of these symptoms. NERLYNX treatment may be stopped or the dose may be lowered if the patient experiences any of these side effects.

Diarrhea

Diarrheais a common side effect ofNERLYNX. The diarrhea may be severe, and you may get dehydrated. Your healthcare provider should prescribe the medicine loperamide for you during your first 2 cycles (56 days) of NERLYNX and then as needed. To help prevent or reduce diarrhea:

Contact your healthcare provider right away if you have severe diarrhea or if you have diarrhea along with weakness, dizziness or fever.

Liver Problems

Changes in liver function tests are common with NERLYNX. The patients doctor will do tests before starting treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. NERLYNX treatment may be stopped or the dose may be lowered if your liver tests show severe problems. Symptoms of liver problems may include tiredness, nausea, vomiting, pain in the right upper stomach area (abdomen), fever, rash, itching or yellowing of your skin or whites of your eyes.

Pregnancy

Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. NERLYNX can harm your unborn baby. Birth control should be used while a patient is receiving NERLYNX and for at least 1 month after the last dose. If patients are exposed to NERLYNX during pregnancy, they must contact their healthcare provider right away.

Common side effects in patients treated with NERLYNX

In clinical studies, the most common side effects seen in patients taking NERLYNX were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis (dry or inflamed mouth, or mouth sores), decreased appetite, muscle spasms, dyspepsia, changes in liver blood test results, nail problems, dry skin, abdominal distention, weight loss and urinary tract infection.

Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 orhttp://www.FDA.gov/medwatch. Patients and caregivers may also report side effects to Puma Biotechnology at 1-844-NERLYNX (1-844-637-5969).

Please see Full Prescribing Information, available at http://www.NERLYNX.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the benefits of NERLYNX and neratinib, the Companys clinical trials and the announcement of data relative to those trials. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has only recently commenced commercialization and shipment of its only FDA approved product; the Companys dependence upon the commercial success of NERLYNX (neratinib); the Companys history of operating losses and its expectation that it will continue to incur losses for the foreseeable future; risks and uncertainties related to the Companys ability to achieve or sustain profitability; the Companys ability to predict its future prospects and forecast its financial performance and growth; failure to obtain sufficient capital to fund the Companys operations; the effectiveness of sales and marketing efforts; the Companys ability to obtain FDA approval or other regulatory approvals in the United States or elsewhere for other indications for neratinib or other product candidates; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Companys drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Companys products; the Companys reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; risks pertaining to securities class action, derivative and defamation lawsuits; the Companys dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006310/en/

Continue reading here:
Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 - Markets Insider

Over $3bn worth of biotechnology products made in Belarus in last five years – Belarus News (BelTA)

Press conference in BelTA's press center

MINSK, 30 August (BelTA) Over $3 billion worth of biotechnology products have been made in Belarus in the last five years, BelTA learned from Emilia Kolomiyets, Director General of the R&D group Chemical Synthesis and Biotechnologies, Director of the Microbiology Institute of the National Academy of Sciences of Belarus (NASB).

According to the source, an essential breakthrough in biotechnologies has been secured in the last few years. Various kinds of biotechnology products worth over $3 billion were made in Belarus in the last five years. Over 170 modern biotechnologies were created over the course of five years. As many as 12 existing manufacturing facilities were upgraded. Eight centers and labs were established as well as nine new enterprises and 39 biotechnology manufacturing facilities.

White and green biotechnologies that cater to the production sector and agriculture are most advanced in Belarus. Those are primarily biodiesel and biogas. These areas are very actively developing. I think in the future efforts will focus on biofuel such as bioethanol and biobutanol. As far as agriculture is concerned, modern farming technologies are being created using biotechnology advances and techniques designed to improve productiveness, noted the director of the Microbiology Institute.

Certain accomplishments have been secured in the area of red biotechnology, which is related to biopharmaceutics and biomedicine. Cell biotechnologies, genome biotechnologies are widely used. Our microbe biotechnologies have moved on, in particular, the synthesis of ferments such as nucleic acids, which are vital for making pharmaceutical substances and ready-made medications. All of it allows us to create original medications, added Emilia Kolomiyets.

Microbial drug with various applications account for a considerable part of the biotechnology products made in Belarus. Agriculture uses biological crop protection agents, microbial fertilizers, probiotics, biological decontaminants, biological preservation agents for vegetable raw materials, ferment products, fodder protein, amino acids, and vitamins. Power engineering industry uses various kinds of biofuel such as biobutanol, bioethanol, biodiesel, and biogas. Healthcare industry uses raw materials for pharmaceutical industry, biopharmaceutic technologies, and diagnostic preparations. Food industry uses yeast, sugar substitutes, food additives, and organic acids.

View post:
Over $3bn worth of biotechnology products made in Belarus in last five years - Belarus News (BelTA)

Powershares Dynamic Biotechnology and Genome Portfolio (PBE) TEMA Trending Higher – FLBC News

Powershares Dynamic Biotechnology and Genome Portfolio (PBE)sTriple Exponential Moving Average has been spotted as trending higher over the past five bars, suggesting that momentum is building for the shares. Triple Exponential Moving Average (also referred to as TEMA) was developed by Patrick Mulloy and was first published in the Technical Analysis of Stocks & Commodities magazine. The main purpose in developing of this indicator was reducing the lag between the indicator and price action by making it fast-acting and more sensitive to market changes. In similar to other moving averages way, the TEMA indicator is used to identify trends and generate trading signals.

The Relative Strength Index (RSI) is another highly popular momentum indicator used for technical analysis. The RSI can help display whether the bulls or the bears are currently strongest in the market. The RSI may be used to help spot points of reversals more accurately. The RSI was developed by J. Welles Wilder. As a general rule, an RSI reading over 70 would signal overbought conditions. A reading under 30 would indicate oversold conditions. As always, the values may need to be adjusted based on the specific stock and market. RSI can also be a valuable tool for trying to spot larger market turns. Powershares Dynamic Biotechnology and Genome Portfolio (PBE) has a 14-day RSI of 63.49, the 7-day is at 73.49, and the 3-day is resting at 85.06.

Powershares Dynamic Biotechnology and Genome Portfolio (PBE) currently has a 14-day Commodity Channel Index (CCI) of 180.47. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Shares of Powershares Dynamic Biotechnology and Genome Portfolio (PBE) have a 200-day moving average of 43.16. The 50-day is 46.48, and the 7-day is sitting at 46.82. Using a bigger time frame to assess the moving average such as the 200-day, may help block out the noise and chaos that is often caused by daily price fluctuations. In some cases, MAs may be used as strong reference points for spotting support and resistance levels.

The Average Directional Index or ADX is technical analysis indicator used to describe if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is 15.56. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend. The Williams Percent Range or Williams %R is another technical indicator that may be useful for traders and investors.

The Williams %R is designed to provide a general sense of when the equity might have reached an extreme and be primed for a reversal. As a general observance, the more overbought or oversold the reading displays, the more likely a reversal may take place. The 14 day Williams %R for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is noted at -1.01. Many consider the equity oversold if the reading is below -80 and overbought if the indicator is between 0 and -20.

Read more here:
Powershares Dynamic Biotechnology and Genome Portfolio (PBE) TEMA Trending Higher - FLBC News

Vacant corner lot by new UB medical school drawing developers’ interest – Buffalo News

A little vacant lot in the Allentown historic district that sits directly across from University at Buffalo's new medical school is becoming a magnet for offers from real estate developers.

The grassy plot at 942 Main St. which has an overgrown community garden, a bench and a decorative stone wall that proclaims "Allentown" is worth only $29,861, according to city property records.

But because of the uptick in developer interest surrounding the Buffalo Niagara Medical Campus and nearby neighborhoods, an owner of the 32.5-foot-by-118-foot parcel says he's received offers hovering in the $500,000 range.

Dino Scouras, the co-owner of the Towne Restaurant in Allentown, co-owns the lot with his brother and sister.

In the last two months, the siblings have received three offers for the vacant lot, said Scouras.

"I'm not surprised by the interest," said Scouras, who owns it along with his brother Paul, and sister, Eleni Konstantopoulos. "That corner is jumping out at everybody."

Scouras said the family is open to offers on the parcel, along with another vacant corner lot it owns at Park and Allen streets which he can see kitty-corner through a window at the Towne restaurant, a 46-year neighborhood fixture at Allen and Elmwood Avenue.

"We're not sure if we'd want to build to suit, or sell the property outright," Scouras said of the 942 Main St. property. "We're open to offers."

Asked if the family would consider developing it for its own business interests, he said: "We're keeping all our options open."

For years, the corner lot has had four large, white stones to provide a unique, decorative element to the corner. The planting bed and decorative stone wall were created by University at Buffalo School of Architecture and Planning students, guided by professor Brad Wales.

More:
Vacant corner lot by new UB medical school drawing developers' interest - Buffalo News

Silencing mosquito gene could slow spread of disease – News from Tulane

A. aegypti mosquitos play a leading role in spreading diseases such as Zika and dengue viruses. (Photo from the Centers for Disease Control)

Next time you slap a mosquito consider this Tulane researchers are testing a strategy to alter the genes of female Aedes aegypti mosquitos so they die soon after a blood meal. A. aegypti mosquitos play a leading role in spreading diseases such as Zika and dengue viruses. The results of this research were published in the June 2017 issue of The FASEB Journal, the journal of the Federation of American Societies for Experimental Biology.

The research team, led by Patricia Y. Scaraffia, assistant professor in the Department of Tropical Medicine and member of the Vector-Borne Infectious Disease Center at the School of Public Health and Tropical Medicine at Tulane University, found that they increased mosquito deaths and decreased egg laying by altering the way female mosquitoes use a crucial protein called xanthine dehydrogenase 1 (XDH1).

XDH1 plays an essential role in blood-fed Aedes aegypti mosquitoes and that silencing of XDH1 gene promotes a blood feeding-induced adulticidal activity, explains Scaraffia. By blocking this gene, the female mosquito cant produce uric acid after a blood meal, which means the mosquitos body cant remove waste. As a result, mosquitos lay fewer eggs and die early.

This novel finding can help researchers to design metabolism-based strategies to control populations of A. aegypti mosquitoes, vectors of diseases of public health significance, says Scaraffia, adding that the teams research has shown that either reducing the amount of XDH1 or blocking it entirely are effective ways to target mosquitos.

Co-authors include Jun Isoe, research scientist at the University of Arizona; Tulane post-doctoral fellow Natthida Petchampai; University of Arizona undergraduate Yurika E. Isoe; Tulane laboratory research scientist Katrina Co; and Stacy Mazzalupo, assistant scientific investigator at The University of Arizona. Financial support came from the Corine Adams Baines Professorship Award and a grant from the U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases Grant (NIH/NIAID).

More:
Silencing mosquito gene could slow spread of disease - News from Tulane

UCLA Human Genetics

The Department of Human Genetics is the youngest basic science department in the Geffen School of Medicine at UCLA. When the Department was launched just prior to the sequencing of the human genome, it was clear that the practice of genetics research would be forever changed by the infusion of massive amounts of new data. Organizing and making sense of this genomic data is one of the greatest scientific challenges ever faced by mankind. The knowledge generated will ultimately transform medicine through patient-specific treatments and prevention strategies.

The Department is dedicated to turning the mountains of raw genetic data into a detailed understanding of the molecular pathogenesis of human disease. The key to such understanding is the realization that genes not only code for specific proteins, but they also control the temporal development and maturation of every living organism through a complex web of interactions.

Housed in the new Gonda Research Center, the Department serves as a focal point for genetics research on the UCLA campus, with state of the art facilities for gene expression, sequencing, genotyping, and bioinformatics. In addition to its research mission, the Department offers many exciting training opportunities for graduate students, postdoctoral fellows, and medical residents. Our faculty and staff welcome inquiries from prospective students. We also hope that a quick look at our web pages will give you a better idea of the Department's research and educational activities.

News Highlights

Follow this link:
UCLA Human Genetics

How do you turn world-leading British science into medicines? – Telegraph.co.uk

Ministers will have their work cut out as the UK has too often failed to translate medical breakthroughs into blockbusters made in Britain. An example is monoclonal antibodies, a common component of biological drugs discovered at Cambridge University in the Seventies.

It led to a Nobel Prize for the scientists involved and has since exploded into a field worth around 70bn globally today. Yet just 3,000 of the 100,000 people working in this area are in Britain. Over the past eight years the UKs historic status as a major net exporter of medicines has been gradually dwindling.

Since 2009, every year bar one has seen a lowering of net exports of pharmaceutical products and medical devices, with the UK even becoming a net importer for the first time on record in 2014, according to UN trade data. So what barriers will industry and the Government have to overcome to make the UK a medicines manufacturing powerhouse once again?

Britains drug makers outlined a blueprint this week for doing just that, in a report entitled Manufacturing Vision for UK Pharma. In it they called on government to invest up to 140m to build a further threedrugmanufacturing centres of excellence, like the one in Stevenage. They also urged pharmaceutical firms to learn from their counterparts in the automotive and aerospace industries on how to partner with government and pool research and development efforts.

View original post here:
How do you turn world-leading British science into medicines? - Telegraph.co.uk

Hurricane Harvey’s path to ‘BREAKING NEWS’ immortality – Washington Post

Cable news channels are forever taking guff for over-deploying their Breaking News banners. Dear CNN, please stop terrorizing me with your breaking news banners! pleaded a viewer distraught over the hyping of marginal and ho-hum news developments. Social media polices these atrocities via endless screenshots and killer snark.

Well, network producers neednt worry about defending themselves for a bit, thanks to the peculiarities of Hurricane Harvey: Its projected to stick around for some time. Via ABC News, heres a timeline for the storm as it barrels* toward the Texas coast:

Friday through Saturday: Harvey is expected to roar ashore the Texas coast as a Category 3 hurricane late Friday evening or early Saturday morning. After that, the storms path remains uncertain but it is forecast to meander near or just inland of the middle of the Texas coast through the weekend.

Sunday through Monday: Some forecast models show Harvey expanding across the Gulf Coast as it makes its way over southern Texas.

Tuesday through Wednesday: The hurricane could, according to some models, move northeast and then re-emerge briefly over the Gulf of Mexico before making a second landfall in northeastern Texas or western Louisiana.

Thats one breaking-news storm. With forecasters talking about three feet of rain resulting from the storm and its aftermath, Harvey could well spin off any number of stories ranging from property damage to impact on locals to the response of the Trump administration. We could be talking about this storm, David [Muir], through the next mid-week and beyond, explained ABC Newss Ginger Zee.

*NPR has warned its people that the verb to barrel should be avoided in discussing Harvey:

The Erik Wemple Blog dissents. Where some see a cliche, we see a classic. A storm isnt a breaking-news-worthy storm until it starts barreling.

Read the rest here:
Hurricane Harvey's path to 'BREAKING NEWS' immortality - Washington Post

Antietam Intimations Of Immortality – DOA

Antietam Intimations Of Immortality

A lot has changed in the world since Antietam last put out an album in 2011. Yet like close comrades Eleventh Dream Day, the continued existence of the group which originally formed way back in 1984 is a source of comfort and a good example of sustainable longevity. Also like the part-time EDD, latter-day whenever its ready release patterns serve Tara Key (vocals/guitars/keyboards), Tim Harris (bass/cello/vocals) and Josh Madell (drums/vocals) well creatively. Now, after another hiatus, the threesome return with a new burst of activity; using their own Motorific Sounds label to funnel archival wares, side-projects and this new Antietam long-player.

Belying the clichs of the bands veteran status, Intimations Of Immortality is a remarkably hungry and omnivorous affair. Reacting somewhat to the preceding taut and back-to-basics Tenth Life, this fresh long-player is a more malleable set-piece. Whilst the raw power-trio set-up still sits at its core, the addition of generous extended-family guest support from Yo La Tengos James McNew (mixing) and Ira Kaplan (piano), band-hopping art-rock pro Sue Garner (backing vocals/production help), The Scene Is Nows Cheryl Kingan (saxes) and Steven Levi (cornet), Special Pillows Katie Gentile (violin) and Louisville bluegrass legend Steve Cooley (mandolin/guitar) fleshes out the recordings to give them added craftsmanship and conviviality.

So whilst theres another strong suite of Patti Smith-infused covert anthems (Sunshine, Jefferson, Is It Time? and Sooner Or Later), the varying combinations of augmenting harmonies, barrelling barroom pianos, soaring strings and rousing horns give them added wider screen touches worthy of a youthful version of The E Street Band. Not to be easily pigeonholed though, the expanded ensemble also stretch out into darker faster Crazy Horse-gone-punk chuggers (Im So Tired, The Fresno Drop and They Dont Know), a terrific garage-rock-meets-New Orleans-carnival instrumental (Birdwatching), staccato art-pop (Right Between Your Eyes) and a pensive yet uplifting jazz-framed wordless homage to Electr-O-Pura-era Yo La Tengo (And Then).

Like Tenth Life before it, the loose live-in-a-room production aesthetics of Intimations Of Immortality can make you work hard to uncover all the melodic details and thought-provoking wordplay, yet overall its also a warmer and more spirited collection that captures Tara Key and co. in self-elevating rude health.

Motorific Sounds

Read more from the original source:
Antietam Intimations Of Immortality - DOA

Genetic engineering: upgrading to human 2.0 – T3

There are two ways to upgrade a human - tinker with biology or augment with technology. So when the time comes to upgrade to human 2.0, should we become Bioshock-style splicers or Halo-esque spartans?

This week we look at the science behind a genetic boost.

Science fiction isnt afraid to mess with genetics. Bioshocks ADAM is a syrup of stem cells augmented with plasmids that carry superhuman genetic traits. Preys Neuromod enhances cognitive abilities by splicing alien genetics into viruses delivered directly into the brain through the eyes. And Prototype's Blacklight gets in to cells and tweaks their genetic code, activating and editing dormant sequences.

So how close are we to game-changing genetic upgrades?

(Image: I.C. Baianu et al.)

The genetic revolution started in the 1950s with two wily Cambridge scientists. With data nabbed from colleagues in London, Watson and Crick deciphered the structure of DNA and opened Pandoras box. Since then, the field has moved fast, and it's littered with Nobel Prizes.

By the mid 1970s, scientists had discovered DNA-snipping molecular scissors known as restriction enzymes, and DNA-stitching enzymes called ligases. It became possible to cut and splice the genetic code, stitching components from different organisms to create recombinant DNA.Bacteria were turned into factories, churning out molecules that they were never intended to make, and genetic engineering began in ernest.

(Image: Bethesda)

In the 1980s, everything sped up. Polymerase chain reaction (PCR) was invented, allowing chunks of DNA to be copied millions of times in a matter of hours. And DNA sequencing became automated, enabling the genetic code to be read faster than ever before.

And the next logical step once you can read the genetic code? Read all of it.

In 2003, the Human Genome Project was completed , revealing the recipe for a human in its entirety. All three billion letters and over 20,000 genes. And, what took an international team decades can now be repeated in days.

We've got the manual to make a human being. We have the tools to read, write and edit DNA. Time to get creative.

(Image: Irrational Games/2K Games)

Interested in making fire with your fingers? Bioshock-style plasmids are already here. Every day scientists stuff them with genes and jam them into cells to give them new abilities.

Real-world plasmids are loops of DNA most often found in bacteria, where they carry genes for useful traits like antibiotic resistance. They replicate independently of the main bacterial genetic code and can be swapped between cells like trading cards that upgrade the microbes' abilities.

And, with a molecular toolkit, they can be cut open and edited, carrying thousands of letters of genetic code like miniature trojan horses.

(Image: Minestrone Soup )

Plasmids can force cells to make new molecules or switch the behaviour of their existing genes. Bacteria will make infinite copies of them on demand. And, they can be frozen down and stored for years.

But, they tend stay out of chromosomes, floating about in the cell and never meshing with the host unless some serious selective pressure is applied.

They're good for a temporary upgrade, but maybe not for a permanent human 2.0 changes. Maybe thats why splicers need a constant ADAM or EVE fix to keep their abilities topped up.

(Image: 2K Games)

Looking for something a little more permanent than a plasmid? Augments in Prey are delivered by viruses, a step up in terms of persistence.

Retroviruses (like HIV) stitch their own genetic code into the code of the cells they infect, permanently merging with their host to ensure that their genes remain active generation after generation. Every time the cell copies its own DNA, it copies the viral genes too.

So, scientists stripped them out, snipping away the genes that cause disease and turning them into empty genetic transport vessels.

(Image: Bethesda Softworks)

Like plasmids, these 'viral vectors' can be stuffed with genetic code, but this time theyll stitch the new genes straight into the cell, adding the new trait permanently. This is the tech is used in Prey to deliver alien genetics into human brains.

Trouble is, viruses aren't that picky about where they choose to integrate. And, if they tuck their DNA right in the middle of something important, they can ruin a crucial gene and destroy the cell they've infected. Worse still, inserting into some genes can cause cancer.

Then there's the problem of getting them to infect the right cells. If you want fire at your fingertips, you'd need a virus that knew the difference between a hand and a foot.

Scientists are working on improving the usability of viral vectors, but to achieve true human 2.0 without the unpredictable side effects, we'll probably need a more targeted approach. Enter CRISPR.

(Image: Thomas Splettstoesser)

Bioshock or Prey-style approaches to gene editing work well, but they're fuzzy and they take time. CRISPR delivers precision genetic manipulation, fast.

Here's how it works.

Viruses, known as bacteriophages, inject their genetic code into bacteria, turning the microbes into miniature virus factories. But the bacteria evolved a way to fight back.

When they come under attack, they store strips of viral genetic code in a CRISPR reference library so that they'll have a head start if the virus returns. When it attacks again, they check the library and an enzyme called Cas9 chops out any matching code, stopping the infection in its tracks.

(Image: National Human Genome Research Institute (NHGRI) from Bethesda, MD, USA)

The great thing about CRISPR is that it's programmable. Give Cas9 a 20-letter strip of genetic code to guide it, and it'll chew up any DNA you want. These are quick and cheap to make in the lab, and the sequence can be made to match all kinds of different genes. And, when the cell goes to repair the cut, you can swoop in with any new DNA you want to add.

The technique has the scientific community so excited that it was named 'breakthrough of the year' by Science in 2015. But is the world about to be overrun with splicers?

(Image: Ingrid Moen et al. 2012)

Splicers can make fire with their hands, hurl balls of ice and cling to the ceiling like spiders. Morgan Yu can morph into a cup, superheat plasma and create telekinetic shields. What could we do with CRISPR at our disposal?

So far, scientists have repaired a gene that causes muscular dystrophy in mice, and they're trialling the technique to reprogram immune cells in people with cancer. We're now in a CRISPR arms race as scientists across the world rush to be the first to make a gene editing breakthrough.

(Image: Bethesda)

It's early days, but the tech has a lot of potential. We could edit single letter mistakes in genetic code, switch genes off, turn genes on, make genetic tweaks. Or, best of all, we could borrow genes from other species and smash them into our cells to acquire traits we were never supposed to have, glow in the dark jellyfish genes, anyone?

In 2010, scientists created the first synthetic cell. In 2016, they designed and built a genome. In the future, it's possible that we could design brand new genes of our own.

Let's face it, this is still a dream, but the toolkit to make it happen is there.

We still don't know what all of our DNA is for, let alone what changes we'd need to make to improve it. Good luck finding the right genes to edit if you're looking to make yourself taller, smarter or funnier, let alone inventing one that'll give you wings.

And then there's the issue of inheritance. Editing adult, or 'somatic', cells could change a person Bioshock-style, but editing sperm and eggs, or 'germline' cells, could change a whole species.

At the moment, genetic engineering tech is moving faster than the regulation to contr
ol it, and it's got scientists worried. We all saw what happened to Rapture when the brakes were taken off scientific advancement.

Gene editing germline cells is restricted in many countries, including the UK, but in July 2017, Chinese scientists got CRISPR working in human embryos for the first time. It was a huge breakthrough, but out of 86 embryos only 28 were successfully edited, and not all of them ended up with the right gene mod at the end.

Rapture, a city where the artist would not fear the censor, where the scientist would not be bound by petty morality, Where the great would not be constrained by the small! And with the sweat of your brow, Rapture can become your city as well.

Luckily, no-one is trying to take edited human embryos all the way though to birth, yet. But, CRISPR opens a whole can of ethical worms, and if youre in any doubt that human modification is coming, watch this.

Pandora's box is open, and we're betting humans of the future will be genetically augmented, but it isn't the only way our species could upgrade. Come back next week when we'll be looking at tech and what it'd take to join the ranks of Halo's Master Chief or Deus Ex's Adam Jensen.

See original here:
Genetic engineering: upgrading to human 2.0 - T3

Around the web: Concerns with human genetic engineering, Gary … – American Enterprise Institute

Should we welcome human genetic engineering? Tyler Cowen

If you could directly alter your kids genetic profile, what would you want? Its hard to know how the social debate would turn out after years of back and forth, but I was dismayed to read one recent research paper by psychologists Rachel M. Latham and Sophie von Stumm. The descriptive title of that work, based on survey evidence, is Mothers want extraversion over conscientiousness or intelligence for their children. Upon reflection, maybe that isnt so surprising, because parents presumably want children who are fun to spend time with.

Would a more extroverted human race be desirable, all things considered? I genuinely dont know, but at the very least I am concerned. The current mix of human personalities and institutions is a delicate balance which, for all of its flaws, has allowed society to survive and progress. Im not looking to make a big roll of the dice on this one.

Amazon robots bring a brave new world to the warehouse The Financial Times

Another way to look at US wage growth The Financial Times

The robot tax gains another advocate Wired

Kim got the idea of a robot tax from Bill Gates, who mentioned it in an interview in February. Since then, shes been meeting with stakeholdersunions and business types and the likeabout how San Francisco, and California, might explore such a thing.

Among the issues with a robot tax: What is a robot? Even roboticists have a hard time agreeing. Does AI that steals a job count as a robot? (Nope, but youd probably want to tax it like one if youre going to commit to this.) Were still working on what defines a robot and what defines job displacement, Kim says. And so announcing the opening of the campaign committee is going to also allow us to have discussions throughout the state in terms of what the actual measure would look like.

Video: Powerball lotteries and the endowment effect Marginal Revolution

3,700-year-old Babylonian tablet rewrites the history of math The Telegraph

Winner-takes-all effects in autonomous cars Benedict Evans

Transcript: Gary Cohn on tax reform and Charlottesville The Financial Times

FT: So what exactly will you have in the tax bill?

GC: On the personal side, we have protected the three big deductions charitable, mortgage and retirement saving. We want to raise the standard deduction caps and get rid of many of the other personal deductions. We want to get rid of death taxes and estate taxes.

On the business side, we are proposing to get rid of many of the deductions that companies can take right now to lower taxable income. At the moment we start with a high corporate tax rate in America but companies use deductions: what we are trying to do is get everyone to pay at a lower rate. This is a big base-broadening exercise.

Revenue may decline in the medium term but it will then explode for the government. When we grow the economy we will see substantial growth in revenue.

The rest is here:
Around the web: Concerns with human genetic engineering, Gary ... - American Enterprise Institute

Three Philly med schools make top-10 list for applications – Philly.com

If youre hoping to attend medical school in Philadelphia, you have a lot of company.

Each year, U.S. News & World Report evaluates medical schools on a variety of measures, such as quality of research and how hard they are to get into. This week, it published a list of the schools that received the most applications for the school year that began in the fall of 2016, with Drexel University, Thomas Jefferson Universitys Kimmel Medical College, and Temple Universitys Katz School of Medicine making the list.

Nationwide that year, 53,029 prospective students applied to a U.S. medical school, U.S. News said, citing data from the Association of American Medical Colleges. Nearly 700,000 applications were submitted to the 118 ranked medical schools that shared their data with U.S. News.

Published: August 25, 2017 1:06 PM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day.We're thankful for your support in every way.

Go here to see the original:
Three Philly med schools make top-10 list for applications - Philly.com